(HealthDay News) — Having a supratherapeutic international normalized ratio (INR) while taking warfarin does not significantly increase the risk for brain bleeding after blunt head trauma in older ...

Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head-to-head trials.

About 1 in 6 patients with GG1 prostate cancer have a higher risk of prostate cancer-specific death, data suggest.

Inverse associations seen between higher adherence to three diets with annual rate of total chronic disease accumulation.

(HealthDay News) — The U.S. Preventive Services Task Force (USPSTF) recommends screening adults for unhealthy alcohol use and providing brief behavioral counseling interventions for those engaged in ...

(HealthDay News) — Patients undergoing major surgery who experience alcohol withdrawal syndrome (AWS) and delirium tremens (DT) face significantly higher risks for complications, according to a study ...

Confirmatory trials for cancer drugs that move from accelerated approval to regular approval often fail to demonstrate evidence of OS or QOL benefits.

A randomized controlled trial tested a model using donor-derived cell-free DNA for predicting graft rejection.